18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

@article{Vandenberghe201018FflutemetamolAI,
  title={18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.},
  author={Rik Vandenberghe and Koen Van Laere and Adrian Ivanoiu and Eric Salmon and Christine Bastin and Eric Triau and Steen G. Hasselbalch and Ian Law and Allan Andersen and Alex Korner and Lennart Minthon and Ga{\"e}tan Garraux and Natalie Nelissen and Guy Bormans and Chris Buckley and Rikard Owenius and Lennart Thurfjell and Gill Farrar and David J. Brooks},
  journal={Annals of neurology},
  year={2010},
  volume={68 3},
  pages={
          319-29
        }
}
OBJECTIVE The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology. METHODS Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15… CONTINUE READING
Highly Cited
This paper has 114 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 175 citations

115 Citations

01020'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 115 citations based on the available data.

See our FAQ for additional information.